Neoplasm Malignant

Oncology·MeSH: Neoplasms

15 drugs in development·4 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
Acetaminophen	Merck & Co., Inc. (MRK)
Calderasib	Merck & Co., Inc. (MRK)
Cetuximab	Merck & Co., Inc. (MRK)
H1 receptor antagonist	Merck & Co., Inc. (MRK)
H2 receptor antagonist	Merck & Co., Inc. (MRK)
MK-1084	Merck & Co., Inc. (MRK)
Patritumab deruxtecan	Merck & Co., Inc. (MRK)

Phase 1(7)

Drug	Company
diphenhydramine	Sanofi (SNY)
naphazoline	Sanofi (SNY)
sar408701	Sanofi (SNY)
sar442257	Sanofi (SNY)
sar442257	Sanofi (SNYNF)
sar443216 iv	Sanofi (SNY)
sar443216 sc	Sanofi (SNY)

Phase 1/Phase 2(1)

Drug	Company
stro-002	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Compare drugs

Acetaminophen vs Calderasib Acetaminophen vs Cetuximab Acetaminophen vs H1 receptor antagonist

Frequently asked questions

How many drugs are in development for Neoplasm Malignant?

BioSniper tracks 15 drugs in development for Neoplasm Malignant across 4 companies.

How many clinical trials target Neoplasm Malignant?

There are 6 clinical trials targeting Neoplasm Malignant tracked by BioSniper.

Deep-dive into Neoplasm Malignant

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Neoplasm Malignant — Drugs in Development & Clinical Trials | BioSniper